Monday, January 13, 2020 7:56:11 AM
Lady Mountbatten is not just a member of the royal family, but one of the closest companions of both the Queen and Prince Philip. Known informally as Penny, the Countess is the only daughter of butcher-turned-businessman Reginald Eastwood and she joined the royal family through her relationship with Norton Knatchbull, 3rd Earl of Mountbatten. Penelope was an immediate hit with the royals, but particularly impressed the Queen and Philip when she was first introduced by Norton in 1975; a royal insider remembered her as "one of the most natural young women I have ever met, outgoing but not brash or flirty."
Lady Penny Mountbatten has thirty years experience in luxury brand representation and event management. She works with over forty top British retailers and luxury hotels, assisting in the execution of their market entry strategies. Her focus is almost entirely on China and she regularly hosts events in the top tier cities, giving presentations and organising events for British brands. With a large network of influential contacts and partners, Penny consistently facilitates opportunities by connecting people and businesses who are looking for investment and distribution.
In the UK, she is committed to guiding each British school, university, luxury brand and hotel to become ‘China ready', advising them on their marketing and the acceptance of Chinese digital payment methods.
Penny is also an Ambassador for some Royal Warranted brands and represents the world renowned Royal portrait artist, Ralph Heimans. As a hands-on Patron of four charities, Penny participates in many fundraising events as well as championing sustainable and organic brands and causes.
Penny is now working closely with Branding Shanghai, an organisation committed to promoting Shanghai and China internationally while at the same time working to bring British culture and brands into China. Together with Branding Shanghai, Penny believes they can bridge the cultures of China and the UK and build upon the strong relationship that already exists between the two countries.
Recent ZIVO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:38:03 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/26/2024 05:36:56 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/26/2024 12:05:12 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 04/09/2024 03:49:14 PM
- Form SCHEDULE 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/14/2024 01:16:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:45:37 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 02/15/2024 01:54:37 PM
- ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study • Business Wire • 02/07/2024 09:54:00 PM
- ZIVO Bioscience Announces Uplisting to OTCQB Market • Business Wire • 01/29/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:11:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 10:17:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:05:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:23:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:12:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 02:29:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:21:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:18:41 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 10/30/2023 05:20:31 PM
- ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens • Business Wire • 10/30/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 12:56:59 PM
- ZIVO Bioscience Announces Reverse Stock Split • Business Wire • 10/26/2023 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/04/2023 09:08:51 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM